Therapeutic potential of Taraxacum officinale against HCV NS5B polymerase: In-vitro and In silico study

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 881-891

  Rehman, Sidra ^a   Ijaz, Bushra ^b   Fatima, Nighat ^a   Muhammad, Syed Aun ^c   Riazuddin, Sheikh ^d  

^a COMSATS Institute of Information Technology ^*  (Pakistan)

^b UNIVERSITY OF THE PUNJAB   (Pakistan)

^c BAHAUDDIN ZAKARIYA UNIVERSITY   (Pakistan)

^d ALLAMA IQBAL MEDICAL COLLEGE   (Pakistan)

Author keywords

Anti HCV; Hepatitis C virus; In vitro; Molecular docking; NS5B polymerase; Taraxacum officinale

Indexed keywords

ANTIVIRUS AGENT; GLUCOPYRANOSIDE; LUTEOLIN; NONSTRUCTURAL PROTEIN 5B; PLANT EXTRACT; QUERCETIN; SOFOSBUVIR; TARAXACUM OFFICINALE EXTRACT; UNCLASSIFIED DRUG; LIGAND; NS-5 PROTEIN, HEPATITIS C VIRUS; PLANT MEDICINAL PRODUCT; VIRAL PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHO CELL LINE; COMPUTER MODEL; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ADSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TARGETING; GENE EXPRESSION; GENOTYPE; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TARAXACUM OFFICINALE; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; COMPUTER SIMULATION; CRICETULUS; DANDELION; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; HEPACIVIRUS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPACIVIRUS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; PHYTOCHEMICALS; PLANT EXTRACTS; TARAXACUM; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84982824816     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.08.002     Document Type: Article

References (48)

1. [1] Gravitz, L., Introduction: a smouldering public-health crisis. Nature 474 (2011), S2–S4.
2. [2] Hanafiah, K.M., Groeger, J., Flaxman, A.D., Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
3. [3] Pécheur, E.-I., Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection. Scientifica, 2012, 2012, 11, 10.6064/2012/709853.
4. [4] Naheed, F., Frequency and determinants of hepatitis C virus infection among females admitted for gynaecological surgeries. J Surg Pak. 17 (2012), 109–111.
5. [5] Qasim, M., 18m hepatitis patients in Pakistan. International The News, 2013 http://www.thenews.com.pk/Todays-News-6-192589-18m-hepatitis-patients-in-Pakistan/.
6. [6] Pawlotsky, J.M., New hepatitis C therapies: the toolbox, strategies and challenges. Gastroenterology 146 (2014), 1176–1192.
7. [7] Khan, M., Khan, M.A., Mujtaba, G., Hussain, M., Ethnobotanical study about medicinal plants of poonch valley azad Kashmir. J. Anim. Plant. Sci. 22 (2012), 493–500.
8. [8] Ahmad, S., Ali, A., Beg, H., Dasti, A., Shinwari, Z., Ethnobotanical studies on some medicinal plants of booni valley, district chitral Pakistan. Pak. J. Weed. Sci. 12 (2006), 183–190.
9. [9] Abbasi, A.M., et al. Ethnopharmacological application of medicinal plants to cure skin diseases and in folk cosmetics among the tribal communities of North-West Frontier Province, Pakistan. J. Ethnopharmacol. 128 (2010), 322–335.
10. [10] Kanwal, A.M.M., Shaukat, S., Javed, R., Ilyas, R., Exploration of ethnomedicinal values of imperative plants of district Gujrat, Pakistan. Middle East J Sci Res. 7 (2011), 397–400.
11. [11] Qureshi, R., Waheed, A., Arshad, M., Umbreen, T., Medico-ethnobotanical inventory of Tehsil Chakwal, Pakistan. Pak. J. Bot. 41 (2009), 529–538.
12. [12] Shinwari, Z.K., Medicinal plants research in Pakistan. J. Med. Plants Res. 4 (2010), 161–176.
13. [13] Mahmood, A., Malik, R.N., Shinwari, Z.K., Mahmood, A., Ethnobotanical survey of plants from Nelum, Azad Jammu and Kashmir, Pakistan. Pakistan J. Bot. 43 (2011), 105–110.
14. [14] Manns, M., Wedemeyer, H., Cornberg, M., Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006), 1350–1359.
15. [15] Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368 (2013), 1878–1887.
16. [16] Wu, J.Z., Hong, Z., Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Curr. Drug Targets Infect. Disord. 3 (2003), 207–219.
17. [17] Altman, S.A., Randers, L., Rao, G., Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol. Prog. 9 (1993), 871–874.
18. [18] Ashfaq, U.A., Javed, T., Rehman, S., Nawaz, Z., Riazuddin, S., Inhibition of HCV 3a core gene through Silymarin and its fractions. Virol. J. 8 (2011), 1–7.
19. [19] Zekri, A.R., Bahnassy, A.A., El-Din, H.M., Salama, H.M., Consensus siRNA for inhibition of HCV genotype-4 replication. J. Virol., 6 p, 2009, p13.
20. [20] Jahan, S., Khaliq, S., Siddiqi, M.H., Anti-apoptotic effect of HCV core gene of genotype 3a in Huh-7 cell line. Virol. J. 8 (2011), 1–7.
21. [21] Villiger, A., Stillhart, C., Parrott, N., Kuentz, M., Using physiologically based pharmacokinetic (PBPK) modelling to gain insights into the effect of physiological factors on oral absorption in paediatric populations. AAPS J. 18 (2016), 933–947.
22. [22] Bickerton, G.R., Quantifying the chemical beauty of drugs. Nat. Chem. 4 (2012), 90–98.
23. [23] Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001), 3–26.
24. [24] Leo, A., Hansch, C., Elkins, D., Partition coefficients and their uses. Chem. Rev. 71 (1971), 525–616.
25. [25] Jassim, A.K.M.N., Farhan, S.A., Noori, O.M., Identification of dandelion taraxacum officinale leaves components and study, its extracts effect on different microorganisms. J. Al. Nahrain Univ. 15 (2012), 7–14.
26. [26] Baba, K., Abe, S., Mizuno, D., Antitumor activity of hot water extract of dandelion Taraxacum officinale: correlation between antitumor activity and timing of administration. Yakugaku Zasshi. 101 (1981), 538–543.
27. [27] Jeon, H., Kang, H., Jung, H., Anti-inflammatory activity of Taraxacum officinale. J. Ethnopharmacol. 115 (2008), 82–88.
28. [28] Park, C.M., Youn, H.J., Chang, H.K., Song, Y.S., TOP1 and 2, polysaccharides from Taraxacum officinale, attenuate CCl4-induced hepatic damage through the modulation of NF-κB and its regulatory mediators. Food Chem. Toxicol. 48 (2010), 1255–1261.
29. [29] Tahtamouni, L.H., Alqurna, N.M., Al-Hudhud, M.Y., Al-Hajj, H.A., Dandelion (Taraxacum officinale) decreases male rat fertility in vivo. J. Ethnopharmacol. 135 (2011), 102–109.
30. [30] Hu, C., Kitts, D.D., Antioxidant, prooxidant, and cytotoxic activities of solvent-fractionated dandelion (Taraxacum officinale) flower extracts in vitro. J. Agric. Food Chem. 51 (2003), 302–310.
31. [31] Ma, L., Hu, Y.D., Li, J.Q., Optimization of ultrasonic extraction process based on central composite design-response surface methodology for luteolin in Taraxacum officinale. Afr. J. Pharm. Pharmacol. 6 (2012), 2075–2082.
32. [32] Colle, D., Arantes, L.P., Rauber, R., Antioxidant properties of Taraxacum officinale fruit extract are involved in the protective effect against cellular death induced by sodium nitroprusside in brain of rats. Pharm. Biol. 50 (2012), 883–891.
33. [33] Tan, S.L., Hepatitis C Viruses: Genomes and Molecular Biology. 2006, Horizon Bioscience, Norfolk (UK).
34. [34] Yasin, T., Riley, T.R., Schreibman, I.R., et al. Current treatment of choice for chronic hepatitis C infection. Infect Drug Resist., 4, 2011, 11.
35. [35] FDA. (USA). Available at: http://www.drugs.com/newdrugs/fda-approves-sovaldi-chronic-hepatitis-c-3986.html/ (2013).
36. [36] Keating, G.M., Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs 75 (2015), 675–685.
37. [37] P. John, D.O. Cunha, The Internet Drug Index, Reviewed on 8/11/2015. http://www.rxlist.com/sovaldi-side-effects-drug-center.htm/ (2015).
38. [38] Schütz, K., Carle, R., Schieber, A., Taraxacum—a review on its phytochemical and pharmacological profile. J. Ethnopharmacol. 107 (2006), 313–323.
39. [39] Sundarrajan, S., Kumari, S., Lulu, S., Arumugam, M., Identification of potent hepatitis C virus RdRp inhibitors by structure based drug designing. J. Bioinf. Cheminf. 1 (2014), 1–14.
40. [40] Wei, Y., Li, J., Qing, J., et al. Discovery of novel hepatitis C virus NS5B polymerase inhibitors by combining random forest, multiple e-pharmacophore modeling and docking. PLoS One, 11, 2016, e0148181.
41. [41] Rajandran, T., Prabhu, R., Prabhu, M., Computer aided docking studies of indole derivatives as Hepatitis C NS5B polymerase inhibitor. Der. Pharm. Chem. 7 (2015), 33–43.
42. [42] El-Awady, M.K., Tabll, A.A., el-Abd, Y.S., et al. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J. Gastroenterol. 12 (2006), 4836–4842.
43. [43] Galani, B.R.T., Sahuc, M.-E., Njayou, F.N., et al. Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. Front. Microbiol., 6, 2015, 488.
44. [44] Wagoner, J., Negash, A., Kane, O.J., Multiple effects of silymarin on the hepatitis C virus life cycle. Hepatology 51 (2010), 1912–1921.
45. [45] Bachmetov, L., Gal-Tanamy, M., Shapira, A., Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J. Viral Hepatitis. 19 (2012), e81–e88.
46. [46] Gonzalez, O., Fontanes, V., Raychaudhuri, S., The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology 50 (2009), 1756–1764.
47. [47] Polyak, S.J., Morishima, C., Shuhart, M.C., Wang, C.C., Liu, Y., Lee, D.Y., Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 132 (2007), 1925–1936.
48. [48] Yi, Z., Sperzel, L., Nurnberger, C., Identification and characterization of the host protein DNAJC14 as a broadly active flavivirus replication modulator. PLoS Pathog., 7, 2011, e1001255.